Making normal hematopoiesis invisible to CAR T cells.
Trends Cancer
; 9(12): 983-984, 2023 12.
Article
en En
| MEDLINE
| ID: mdl-37863719
Two recent studies, by Casirati et al. and Wellhausen et al., report genetically engineering normal hematopoietic stem and progenitor cells (HSPCs) to be resistant to chimeric antigen receptor (CAR)-T cells, by changing a single amino acid in the target protein that abrogates CAR binding, without compromising protein function. This allows for selective targeting of cancer cells without harming normal hematopoietic cells.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Células Madre Hematopoyéticas
/
Linfocitos T
Límite:
Humans
Idioma:
En
Revista:
Trends Cancer
Año:
2023
Tipo del documento:
Article
Pais de publicación:
Estados Unidos